首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S
【24h】

Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S

机译:抗凝血酶,蛋白C和蛋白S遗传性缺陷的循环微粒和血栓形成风险

获取原文
获取原文并翻译 | 示例
           

摘要

Many subjects carrying inherited thrombophilic defects will never experience venous thromboembolism (VTE) while other individuals developed recurrent VTE with no known additional risk factors. High levels of circulating microparticles (MP) have been associated with increased risk of VTE in patients with factor V Leiden and prothrombin G20210A mutation, suggesting a possible contribution of MP in the hypercoagulability of mild genetic thrombophilia. The role of MP as additional risk factor of VTE in carriers of natural clotting inhibitors defects (severe thrombophilia) has never been assessed. Plasma levels of annexin V-MP, endothelial-derived MP (EMP), platelet-derived MP (PMP), tissue factor-bearing MP (TF+) and the MP procoagulant activity (PPL) were measured in 132 carriers of natural anticoagulant deficiencies (25 antithrombin, 63 protein C and 64 protein S defect) and in 132 age and gender-matched healthy controls. Carriers of natural anticoagulant deficiencies, overall and separately considered, presented with higher median levels of annexin V-MP, EMP, PMP, TF+ MP and PPL activity than healthy controls (p<0.001, <0.001, <0.01, 0.025 and 0.03, respectively). Symptomatic carriers with a previous episode of VTE had significantly higher median levels of annexin-V MP than those without VTE (p=0.027). Carriers with high levels of annexin V-MP, EMP and PMP had an adjusted OR for VTE of 3.36 (95 % CI, 1.59 to 7.11), 9.26 (95 % CI, 3.55 to 24.1) and 2.72 (95 % CI, 1.16 to 6.38), respectively. Elevated levels of circulating MP can play a role in carriers of mild and severe inherited thrombophilia. The clinical implications of this association remain to be defined.
机译:许多携带遗传性血栓形成性缺陷的受试者将永远不会经历静脉血栓栓塞(VTE),而其他个体则发展为复发性VTE,而没有已知的其他危险因素。高水平的循环微粒(MP)与V型莱顿因子和凝血酶原G20210A突变患者的VTE风险增加有关,表明MP可能在轻度遗传性血友病的高凝状态中起作用。从未评估过MP作为天然凝血抑制剂缺陷(严重血栓形成)携带者中VTE的其他危险因素的作用。在132例自然抗凝缺乏症患者中测量了血浆膜联蛋白V-MP,内皮源性MP(EMP),血小板源性MP(PMP),组织因子MP(TF +)和MP促凝血活性(PPL)( 25个抗凝血酶,63个蛋白C和64个蛋白S缺陷)以及132个年龄和性别匹配的健康对照组。整体和单独考虑的天然抗凝剂缺乏症患者的膜联蛋白V-MP,EMP,PMP,TF + MP和PPL活性中值水平均高于健康对照组(分别为p <0.001,<0.001,<0.01、0.025和0.03 )。有VTE发作的有症状携带者的膜联蛋白-V MP中位数水平明显高于无VTE者(p = 0.027)。膜联蛋白V-MP,EMP和PMP水平高的载体的VTE调整后OR为3.36(95%CI,1.59至7.11),9.26(95%CI,3.55至24.1)和2.72(95%CI,1.16至1.26) 6.38)。循环MP水平升高可在轻度和重度遗传性血友病患者中发挥作用。这种关联的临床意义尚待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号